Is pharma walking the walk when it comes to patient centricity?

In his recent article for PharmaTimes, Monmouth Director, Mark Duman, questions whether the pharmaceutical industry is truly engaging with patients.  Mark argues that patient centricity is not just about the end product or services but is about integrating patient and public views into the whole lifecycle of a medicine or device, from bench to bedside. 

Mark claims that while it’s easy to talk about the need for patient centrcity in mission statements and speeches, it’s another matter to put it into everyday practice.

A workshop facilitated by Monmouth Partners for NHS England, under the Medicines Optimisation banner, asked patients and carers to explore How we make medicines-taking a better experience?

With the agenda defined by patients themselves, the workshop focused on the need to better understand them as individuals – not just as patients, conditions, or medicines.

Mark urges that at the end of the day we are all patients, or at least caregivers, even if just to ourselves.  Let those experiences guide the pharmaceutical industry, and the broader healthcare system, to not just talk the talk, but to actually walk it.

To read Mark’s full article in PharmaTimes please click here.

Latest content:


NHS services under pressure – What legacy will Covid-19 leave?

Back in August we looked at the impact of the pandemic on NHS cancer services. The concern then was that patients were not being seen or treated quickly enough or in some cases, given the drop-off in activity, not being diagnosed in the first place. Given the false dawn lull in Covid cases back in the summer, now all too clearly the calm before the storm, what is the situation now?

Read More »
Please accept [renew_consent]%cookie_types[/renew_consent] cookies to watch this video.

Tracking the Pandemic and its impact